MICALL1: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: MICALL1

NCBI ID: G85377

MICALL1

MICALL1: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. The most common cause of Parkinson's disease is the neurodegenerative motor disorder, which is characterized by symptoms such as tremors, rigidity, and bradykinesia. MICALL1, a protein that has been shown to interact with Rab13, a protein that is involved in the regulation of cell division and differentiation, may be a drug target and biomarker for Parkinson's disease.

MICALL1 is a protein that is expressed in various tissues and has been shown to play a role in the development and progression of neurodegenerative diseases. MICALL1 has been shown to interact with a variety of proteins, including Rab13. This interaction between MICALL1 and Rab13 has been shown to play a role in the regulation of cell division and differentiation, as well as in the development of neurodegenerative diseases.

One of the most promising aspects of MICALL1 is its potential as a drug target. The neurodegenerative motor disorder is a debilitating condition that is often treated with drugs that target dopamine-producing neurons. However, these drugs often have limited efficacy and can cause potential side effects. By targeting MICALL1, researchers may be able to develop more effective therapies for Parkinson's disease.

In addition to its potential as a drug target, MICALL1 may also be a useful biomarker for the diagnosis and progression of Parkinson's disease. The progressive loss of dopamine-producing neurons in Parkinson's disease is often detected using brain imaging techniques, such as positron emission tomography (PET) or functional magnetic resonance imaging (fMRI). However, these techniques are not always accurate or reliable. By studying the levels of MICALL1 in brain tissue, researchers may be able to more accurately diagnose and monitor the progression of Parkinson's disease.

MICALL1 has also been shown to interact with other proteins that are involved in the regulation of cell division and differentiation. This suggests that MICALL1 may be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Huntington's disease. By studying the role of MICALL1 in these diseases, researchers may be able to develop new treatments and therapies for these debilitating conditions.

In conclusion, MICALL1 is a protein that has been shown to interact with Rab13, a protein that is involved in the regulation of cell division and differentiation. These interactions suggest that MICALL1 may be a drug target and biomarker for Parkinson's disease, as well as for other neurodegenerative conditions. Further research is needed to fully understand the role of MICALL1 in these diseases and to develop effective treatments. By studying the effects of MICALL1 on the regulation of cell division and differentiation, researchers may be able to develop new therapies for Parkinson's disease and other debilitating conditions.

Protein Name: MICAL Like 1

Functions: Probable lipid-binding protein with higher affinity for phosphatidic acid, a lipid enriched in recycling endosome membranes. On endosome membranes, may act as a downstream effector of Rab proteins recruiting cytosolic proteins to regulate membrane tubulation. May be involved in a late step of receptor-mediated endocytosis regulating for instance endocytosed-EGF receptor trafficking. Alternatively, may regulate slow endocytic recycling of endocytosed proteins back to the plasma membrane. May indirectly play a role in neurite outgrowth

The "MICALL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICALL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets